Preview Mode Links will not work in preview mode

Rheuminations


Aug 18, 2020

Part 2 of this series explores how we began to measure antibody levels and how serotherapy evolved and was used to investigate multiple diseases (I’m looking at you, pneumonia). We’ll also learn how advances in laboratory techniques like electrophoresis paved the way for a better understanding of the antibody.

  • Intro :11
  • In this episode :15
  • Recap of Part 1 :22
  • In this episode :53
  • The mechanism of action was theoretical 2:30
  • The story of convalescent serum 6:22
  • Pneumonia: “The captain of the men of death” 6:58
  • How culturing was done then 10:56
  • A big break: Isolating the antibody 14:26
  • A 30,000-foot look at pneumonia 17:13
  • Type 1 pneumonia trials 20:20
  • 1918 influenza pandemic 23:31
  • Measles 27:59
  • The story of the antibody 30:30
  • More fun naming conventions 35:25
  • Cone fractionation 38:35
  • Quick summary 42:20
  • Thanks for listening! 44:27

Disclosure: Brown reports no relevant financial disclosures.

We’d love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum

References:

Black CA. Immunol Cell Biol. 1997;doi: 10.1038/icb.1997.10.

Bullowa JGM. JAMA. 1928;90:1354-1358.

Cecil RL, Sutliff WD. JAMA. 1928;91:2035-2042.

Felton LD. Boston Med Surg J. 1924;190:819-825.

Hooper JA. LymphoSign Journal. 2015;2 181-194.

Luke TC, et al. Ann Intern Med. 2006;145:599-609.

McGuire LW, Redden WR. Am J Public Health. 1918. 741-744.

McKhann CF, Chu FT. Am J Dis Child. 1933;45:475-479.

Podolsky SH. Am J Public Health. 2005;95:2144-2154.

Podolsky SH. J R Soc Med. 2009;102:203-207.

Tiselius A, Kabat EA. J Exp Med. 1939;69:119-131.